Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-97,083
Closed -$9.07M 119
2023
Q3
$9.07M Sell
97,083
-1,431
-1% -$132K 1.46% 14
2023
Q2
$9.01M Buy
98,514
+1,667
+2% +$137K 1.29% 26
2023
Q1
$7.12M Buy
96,847
+39,010
+67% +$3.37M 1.08% 48
2022
Q4
$4.83M Sell
57,837
-1,428
-2% -$129K 0.79% 65
2022
Q3
$5.74M Buy
+59,265
New +$7.07M 0.99% 59
2021
Q1
Sell
-38,582
Closed -$11.3M 119
2020
Q4
$11.3M Buy
38,582
+1,251
+3% +$321K 1.2% 22
2020
Q3
$8.83M Sell
37,331
-970
-3% -$221K 1.29% 10
2020
Q2
$7.6M Buy
38,301
+7,384
+24% +$1.38M 1.22% 24
2020
Q1
$5.67M Sell
30,917
-11,424
-27% -$2.03M 1.26% 27
2019
Q4
$7.07M Buy
+42,341
New +$6.3M 1.16% 35
2018
Q4
Sell
-72,210
Closed -$9.02M 110
2018
Q3
$9.02M Sell
72,210
-30,411
-30% -$3.36M 1.14% 26
2018
Q2
$8.77M Buy
+102,621
New +$7.54M 1.21% 12
2016
Q3
Sell
-114,262
Closed -$5.77M 116
2016
Q2
$5.77M Buy
114,262
+1,757
+2% +$88.7K 1.05% 34
2016
Q1
$5.44M Buy
+112,505
New +$4.34M 1.05% 40

Other funds holding AMED

Pier Capital's AMED Position: Q4 2023 in Review

Pier Capital sold out of Amedisys (AMED) in Q4 2023, closing a stake of 97,083 shares — an estimated $9.07M sold.

Pier Capital first reported a position in AMED in Q1 2016 and held it in 14 quarters. The position peaked at $11.3M in Q4 2020. 288 funds tracked by Wall St. Rank hold AMED as of Q4 2023.

  • Pier Capital reported no remaining Amedisys position as of Q4 2023 after selling out during the quarter.
  • Pier Capital sold 97,083 Amedisys shares in Q4 2023, an estimated $9.07M.
  • Pier Capital first reported a position in Amedisys in Q1 2016 and held it in 14 quarters.
  • Pier Capital's Amedisys position peaked at $11.3M in Q4 2020.
  • 288 funds tracked by Wall St. Rank held Amedisys as of Q4 2023.

Based on Pier Capital's 13F filing for Q4 2023, filed 15 Feb 2024.